STAT Plus: Generic group fails again to block California law that bans pay-to-delay deals
ADOBE
“California’s law has made it more difficult for patients to access more affordable generic and biosimilar medicines," says Jeffrey Francer, who heads AAM.
No hay comentarios:
Publicar un comentario